Doylestown, Pa.-based FlowMetric Life Sciences Inc., has launched the VaxEffect COVID-19 Vaccine Immune Response Test, a platform exclusively created to quantitatively assess and track, now and over time, an individual’s immune response to any of the COVID-19 vaccines currently available in the United States.
Initially available through healthcare providers, the VaxEffect test will provide a personalized, and clinically accurate readout of a person’s COVID-19 specific antibody levels, either generated in response to the COVID-19 vaccine or to prior exposure to the SARS-CoV-2 virus. With simple, repeat testing, changes in these antibody levels can be tracked over time utilizing easy-to-read longitudinal reports, to better inform vaccine-based healthcare decisions and to support the optimal use of booster vaccinations as they become available.
“The VaxEffect test will be especially important for patients with immune compromised conditions such as those fighting cancer, diabetes, auto-immune disorders, or those that are immunosuppressed due to organ transplantation, who may have not generated a strong immune response to the vaccine,” says Grant Morgan, PhD, general manager of VaxEffect and EVP of FlowMetric Life Sciences Inc.
Unlike other antibody tests, VaxEffect is the first COVID serology test built on a multiparameter flow cytometry platform that is designed to differentiate between infection and vaccination based on an antibody profile. Using this proven, powerful, and precise technology, the VaxEffect Test is both 99%+ sensitive and 99%+ specific.
This laboratory-developed test has not been reviewed or approved by the FDA. The FDA has determined that such review or approval is not required.